Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory

Part 1. Basic concepts

Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.

Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu

Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo

Chapter 3. Economics of pharmacogenomic testing in clinical practice

Alan H.B. Wu

Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

Part 2. Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5. Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6. Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7. Thiopurines

Terreia S. Jones, Mary V. Relling

Part 3. Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9. Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10. DNA-Guided Statin Therapy

Gualberto Rua?o, Richard L. Seip, Jorge Duconge

Chapter 11. The statin response gene: Kif6

....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.

Part 4. Drugs that cause delayed hypersensitivity

Chapter 12. Abacavir

Elizabeth J. Phillips, Simon A. Mallal

Chapter 13. Allopurinol

Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen

Chapter 14. Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16. Immunosuppressants Pharmacogenomics

Ping Wang

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

Part 2. Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5. Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6. Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7. Thiopurines

Terreia S. Jones, Mary V. Relling

Part 3. Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9. Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10. DNA-Guided Statin Therapy

Gualberto Rua?o, Richard L. Seip, Jorge Duconge

Chapter 11. The statin response gene: Kif6

..............